The Potential of ALLO-715 in Relapsed/Refractory Multiple Myeloma: Doris Hansen, MD
The hematologist from Moffitt Cancer Center discussed the promise of ALLO-715 in relapsed/refractory multiple myeloma.
Ide-Cel's Benefit on PF Survival: Doris Hansen, MD
The hematologist from Moffitt Cancer Center discussed the survival benefit of ide-cel in the phase 2 KarMMa trial.